Pipeline

Peptimmune pipeline and strategy

Pipeline Highlights

Product pipeline focused on chronic and progressive disorders
Product profile designed to improve patient compliance and decrease side effects associated with current treatments
Addressing large or significantly under served markets

Change Text Size:

Recent News

Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis

7/30/2008 – Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,381,790 (the '790 patent) which protects the…

Peptimmune Announces the Second Close of Series D Private Financing

7/16/2008 – Peptimmune announced that it has completed a second close of $8.9 million of its Series D preferred stock offering with its investor syndicate led by New…

Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008

6/17/2008 – Peptimmune announces first patient dosed in a phase Ib study of PI-2301 in multiple sclerosis patients in one of the most comprehensive studies of the…

View more articles in the News Archives